Form 4: Pfizer Executive Christoffel Boshoff Reports Stock Transactions

Executive Vice President Christoffel Boshoff reports multiple transactions involving Pfizer Inc. (PFE) common stock, including the exercise of stock appreciation rights and vesting of performance share awards.

Summary

• Christoffel Boshoff, an Executive Vice President at Pfizer Inc., filed a Form 4 detailing changes in beneficial ownership of Pfizer stock.
• On February 23, 2024, Boshoff exercised stock appreciation rights, acquiring 9,752 shares at a price of $27.34.
• Also on February 23, 2024, shares were withheld to satisfy tax obligations related to vesting restricted stock units and earn-out of stock appreciation rights.
• On February 25, 2024, Boshoff earned out performance share awards, acquiring 15,455 shares.
• Additional shares were withheld on February 25, 2024, to cover tax obligations related to the performance share awards.
• Boshoff's total direct holdings of Pfizer common stock after these transactions amount to 148,647 shares.
• Boshoff also indirectly owns 624 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reflects routine executive compensation transactions. The earn-out of performance shares is mildly positive, suggesting the achievement of performance goals.

Positives

• The earn-out of performance share awards suggests that performance metrics were met, which could be viewed positively.

Industry Context

Executive stock transactions are a normal part of corporate governance and compensation practices in the pharmaceutical industry. Monitoring these transactions can provide insights into executive sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry typically include a mix of salary, stock options, restricted stock units, and performance-based awards.
• The vesting of performance share awards suggests that Pfizer's performance met certain pre-defined targets, which is a common practice among large pharmaceutical companies like Johnson & Johnson (JNJ) and Merck (MRK).
• The withholding of shares to cover tax obligations is a standard procedure in executive compensation plans across various industries.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• Employees may be indirectly impacted by the performance share awards, as they are tied to company performance.

Key Dates